Stockscreener 앱 받기
2.57
2.39%
0.06
시간 외 거래:
2.55
-0.02
-0.78%
전일 마감가:
$2.51
열려 있는:
$2.54
하루 거래량:
495.32K
Relative Volume:
0.20
시가총액:
$275.04M
수익:
$31.25M
순이익/손실:
$-88.48M
주가수익비율:
-2.0236
EPS:
-1.27
순현금흐름:
$-79.63M
1주 성능:
+4.05%
1개월 성능:
-21.17%
6개월 성능:
+94.70%
1년 성능:
+117.80%
1일 변동 폭
$2.46
$2.59
1주일 범위
$2.31
$2.59
52주 변동 폭
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.57 | 275.04M | 31.25M | -88.48M | -79.63M | -1.27 |
|
TMO
Thermo Fisher Scientific Inc
|
559.65 | 214.07B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
238.36 | 172.16B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
147.36 | 42.09B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.36 | 35.82B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
419.26 | 34.33B | 3.84B | 866.24M | 792.60M | 10.37 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat
Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World
Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN
HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN
ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World
HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World
HighTower Advisors LLC Trims Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday - Benzinga
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls - Nasdaq
HC Wainwright Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to "Buy" - MarketBeat
Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $8.80 - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $8.80 - MarketBeat
Fmr LLC Cuts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 59.0% in November - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. announced that it expects to receive $79.999999 million in funding from a group of investors - Marketscreener.com
Finance Watch: PIPEs Still Key Even As FOPO Fundraising Climbs - News & Insights
Wayne’s Aclaris Therapeutics Signs Exclusive Licensing Deal with Chinese Biotech - MSN
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Connor Clark & Lunn Investment Management Ltd. Grows Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decrease in Short Interest - Defense World
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.02%
자본화:
|
볼륨(24시간):